Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: US Adds To Antibody Push With $486m AstraZeneca Deal

Plus: Bharat To Start Phase III Vaccine Trials Shortly

Executive Summary

After a week of monoclonal antibody therapies hitting the headlines - including a personal endorsement from President Trump - the US government bulks up its potential supplies. AZ's long-acting monoclonal antibody product enters large-scale trials for both a treatment and prophylaxis of COVID-19.

You may also be interested in...



Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch

As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.

Coronavirus Update: Praised By Trump, Regeneron Files Antibody Cocktail For Emergency Use Authorization

Trump's praise of the therapy and talk of a 'cure' for COVID-19 has raised concerns about misinformation and pressure on the US FDA once again.

Can Avigan Bite Into Buzzing Indian Favipiravir Market?

Fujifilm Toyama’s favipiravir may be relatively late on the Indian market,but local partner Dr Reddy’s believes that the large amount of safety data and superior shelf life of the product will hold it in good stead amid heightened competition. Local manufacturing could also help Dr Reddy’s pare the price differential with other versions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel